1	Validation and performance evaluation of a novel interferon- γ release assay for the detection of
2	SARS-CoV-2 specific T-cell response
3	
4	Daniela Huzly ^{1*} , Marcus Panning ^{1*} , Franziska Smely ¹ , Martin Enders ² , Johanna Komp ³ , Daniel
5	Steinmann ⁴
6	
7	
8	¹ Institute of Virology, Medical Center - University of Freiburg, Faculty of Medicine, University of
9	Freiburg, Freiburg, Germany
10	² Laboratory Prof. Gisela Enders and Colleagues, Stuttgart, Germany
11	³ Institute of Microbiology, Medical Center - University of Freiburg, Faculty of Medicine, University of
12	Freiburg, Freiburg, Germany
13	⁴ Occupational Medical Service, Medical Center - University of Freiburg, Faculty of Medicine,
14	University of Freiburg, Freiburg, Germany
15	
16	* contributed equally
17	Contributed equally
18	
19	
20	Corresponding author:
21	Daniela Huzly, MD, Institute of Virology, Hermann-Herder-Str. 11, 79106 Freiburg, Germany. Phone
22	++49 761 203 6609 Email: daniela.huzly@uniklinik-freiburg.de
23	
24	
25	Word count abstract: 224
26	Word count manuscript: 3205
	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

2

Abstract Background: The reliable detection of the T-cell mediated response to COVID-19 or COVID-19 vaccination is important for individual patient care and for monitoring the immune response e.g. in COVID-19 vaccine trials in a standardized fashion. Methods: We used blood samples from health care workers (HCW) with or without history of COVID-19 to define test accuracy of a novel interferon-γ release assay. Usefulness of qualitative and quantitative results after COVID-19 vaccination was examined in HCW receiving homologous or heterologous vaccination regimens. For a real-life performance evaluation, we analysed interferon-γ response to complete vaccination in 149 patients receiving immunosuppressive or immune modulating therapies. Results: Using a double-cut-off strategy integrating the result of background stimulation the assay had a specificity of 100%. Sensitivity of the IGRA was 83.5 and 100% in HCW after SARS-CoV-2 infection more or less than 6 months ago. Quantitative results showed significant differences between first and second vaccine dose, but no difference between homologous and heterologous vaccination regimen. The majority of immunocompromised patients showed no immune response or isolated T-cell or antibody response to complete vaccination. Conclusions: The novel IGRA proved to be a highly specific and sensitive tool to detect the SARS-CoV-2 specific T-cell response to COVID-19 as well as COVID-19 vaccination. In perspective, it may serve as a standardized tool in COVID-19 vaccine trials and in clinical care of immunosuppressed patients. Key words: SARS-CoV-2; adaptive immune response; IFNγ release assay; validation; health care workers; immunosuppressed patients

Introduction The role of the T-cell immune response in SARS-CoV-2 infection is not entirely understood, but data from animal models show an important role for protection against coronavirus disease 2019 (COVID-19) mediated by CD4⁺ and CD8⁺ T cells and the production of interferon gamma (IFN- γ) [1, 2]. Since December 2020, the first vaccines against COVID-19 are available but the quality and duration of the immune response to vaccination remains unclear as of yet. Although numerous SARS-CoV-2 antibody detection assays were introduced with unprecedented speed and are now widely in use, the implementation of T cell assays lagged behind. However, besides analysing the antibody response, it will be of importance to investigate the T- cell mediated immune response, e.g. in vaccine trials or in a clinical setting for individual patient care. Therefore, easy to perform, validated, and ideally standardized T-cell assays are required [3]. Here we evaluated a novel commercially available IFN-γ release assay (IGRA) to analyse the SARS-CoV-2 specific T- cell response. IGRA have revolutionized the diagnosis of tuberculosis [4] and several other pathogens [5, 6]. In experimental settings, in-house SARS-CoV-2 IGRA were introduced recently [7]. The main advantage of this type of assay is the possibility to perform them without special equipment and with very short hands-on time. The IFN- γ results are expressed in international units and are therefore truly quantitative. For our evaluation study, we asked immunocompetent healthcare workers (HCW) at Freiburg University Hospital to participate and offered measurement of SARS-CoV-2 antibodies. One group comprised HCW who had experienced mild SARS-CoV-2 infection in 2020 and another group had been vaccinated against COVID-19. For negative controls, we asked HCW without a history of COVID-19 prior to vaccination. After successful evaluation of the assay, we analysed the COVID-19 vaccine associated T-cell immune response in several patient groups including immunocompromised patients to evaluate

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

the test performance in a real-life setting.

Methods

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

Study population

A total of 230 HCW agreed to participate. Of these, 107 had previous SARS-CoV-2 infection (COVID-19 group) proven by a positive SARS-CoV-2 RT-PCR and seroconversion. In the vaccine group, 38 were tested three weeks after the first and two weeks after the second dose of vaccination with BNT162b2 (Comirnaty®, BioNTech/Pfizer). Another 30 HCW were analysed three to four weeks after the first dose of vaccination with AZD1222 (Vaxzevria®, AstraZeneca). Of these 30 AZD1222 vacinees, 27 received a heterologous vaccination scheme with a second dose of mRNA-1273 (COVID-19 vaccine Moderna®, Moderna Biotech) and were sampled two weeks hereafter. Finally, 55 HCW were without history of SARS-CoV-2 infection or vaccination (no COVID-19 group). The Department of Occupational Medicine collected the HCW samples after informed consent. From all participants a serum sample was drawn for SARS-CoV-2 antibody testing together with a heparinized whole blood sample for the IGRA. Samples were tested independently without knowledge of SARS-CoV-2 antibody status or patient history. In the first three cases with blank control result above 100 mIU/ml, a second heparinized whole blood sample was drawn to exclude sampling error. For the real-life performance evaluation, all patient samples (n=149) sent to our routine diagnostic laboratory with the request for SARS-CoV-2 Tcell analysis and antibody detection after COVID-19 vaccination were included. Patients received various immunosuppressive or immune modulating therapies.

SARS-CoV-2 interferon-γ release assay

The SARS-CoV-2 IGRA (EUROIMMUN, Lübeck, Germany) is based on the SARS-CoV-2 spike protein and was done according to the manufacturer's instructions. A set of three tubes is required per whole blood sample: 1) SARS-CoV-2 IGRA BLANK without interferon activating substance to define the individual background stimulation. 2) SARS-CoV-2 IGRA TUBE containing antigens based on the S1 domain of SARS-CoV-2 spike protein. 3) SARS-CoV-2 IGRA STIM containing a mitogen for unspecific interferon stimulation for testing the viability and stimulation capacity of T cells and sufficient number of T cells in the whole blood samples. In brief, 500 μl of heparinized whole blood samples were used and incubated at 37 °C for 20 h to 24 h. After incubation, tubes were centrifuged at 8,000g for 10 min

and 200 μ l of supernatant was stored at 2-8 °C until measurement. For the IFN- γ enzyme-linked immunosorbent assay (ELISA), supernatant was diluted 1:5 with dilution buffer. Optical density (O.D.) was measured at 450 nm after enzymatic reaction. A set of six standards and two controls was used for each run. Samples with IFN- γ values above the standard curve were further diluted 1:10, 1:50 or 1:100, depending on the O.D. of the initial measurement. The manufacturer defined cut off is at >200 mIU/ml including a grey zone of 100 – 200 mIU/ml.

Detection of SARS-CoV-2 antibodies

We used the following SARS-CoV-2 immunoglobuline G (IgG) assays to rule out past infection in the no COVID-19 and in the vaccine cohorts: Anti-SARS-CoV-2 ELISA IgG, detecting IgG antibodies against S1 (EUROIMMUN, Lübeck, Germany); recomWell SARS-CoV-2 IgG detecting IgG antibodies against the nucleoprotein (N) (Mikrogen, Munich, Germany); ADVIA Centaur SARS-CoV-2 total antibody (COV2T) assay, detecting total antibodies against S1-RBD (Siemens, Munich, Germany); and the Elecsys Anti-SARS-CoV-2, detecting total antibodies against N (Roche, Mannheim, Germany). Quantitative antibody levels as well as functional analysis of antibodies in the COVID-19 and vaccine groups are subject of a separate study.

Statistical analysis

Data were analysed using IBM SPSS Statistics version 24 software (www.ibm.com/spss/statistics), GraphPad Prism version 9 (www.graphpad.com), and MedCalc version 19 (www.medcalc.com). We determined test accuracy, positive and negative predictive values and likelihood ratios assuming a disease prevalence of 10% and using only measured values of individuals after SARS-CoV-2 RT-PCR-and seroconversion- proven infection. For test accuracy calculation, we used two different approaches: we defined grey zone results as either positive or negative. As data had a non-Gaussian distribution, we used nonparametric tests throughout, a Mann-Whitney U test for single unpaired and Wilcoxon matched-pairs signed rank test for paired comparisons of medians. Receiver operating characteristic (ROC) analysis was used to define an optimum cut-off value at the Youden maximum index value. We calculated coefficient of variation for intra- and inter-assay variability. All raw data can be found in the supplementary file.

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

6

defining IFN-γ concentrations 200 mIU/ml as true positive to detect SARS-CoV-2 infection in samples

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

7

vaccination (6 and 9 mIU/ml), but subsequently reacted after the second dose of BNT162b2. In

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

8

scheme AZD1222/BNT162b2. Of note, most responding patients had isolated T-cell or antibody

response (Table 5). 13 of 20 patients who had received B-cell depleting therapy up to 12 months ago had isolated T-cell response with IFN- γ release >1000 mIU/ml.

Discussion

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

In this study, the EUROIMMUN SARS-CoV-2 IGRA demonstrated a cut-off dependent specificity of 96.3-100% and sensitivity of 75.4-89.6%. We used a rigorously tested set of samples to evaluate the IGRA thoroughly. The IGRA proved to be a sensitive and specific tool for detecting the cellular immune response to COVID-19 or COVID-19 vaccination. Technically, it is easy to perform and can be rapidly implemented in routine diagnostic laboratories. This will assist e.g. in patient care and future COVID-19 vaccination trials as it will allow on site testing of the cellular immune response using standardized and widely available assays.

Understanding the immune response to COVID-19 is essential for the development of preventive strategies against COVID-19. Since the end of 2020 several vaccines have been authorized by medicines agencies worldwide and mass vaccination campaigns in some countries have been very successful in reducing case numbers significantly [8, 9]. Nevertheless, breakthrough infections have been reported to occur with all vaccines and it will be important to define the correlates of protection after vaccination as well as after infection [10-14]. Serological assays to quantify SARS-CoV-2 specific antibodies against spike protein (S1) or the receptor binding domain as well as surrogate neutralization assays for the detection of protective antibodies have been described [15, 16]. However, from recent communications of breakthrough infections in healthy and immunosuppressed adults it appears that the humoral response alone may not be sufficient for protection against infection and disease [11, 14, 17]. Longitudinal studies of COVID-19 patients have observed a significant association of a specific T cell response with milder disease in the absence of SARS-CoV-2 IgG seroconversion and even in agammaglobulinaemic and B-cell depleted patients suggesting that T cell responses may be important for control of SARS-CoV-2 infection [18-24]. Of note, T cell-responses in convalescents and after COVID-19 vaccination seem not to be affected by mutations found in SARS-CoV-2 variants of concern [25-28], whereas neutralizing capacity of antibodies is significantly reduced [29]. It is therefore of importance to measure T-cell mediated reactivity to evaluate immune response to vaccination.

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

coronavirus infections.

11

Diagnosis of past infection without history of PCR positivity is difficult using SARS-CoV-2 antibody-based testing alone, as antibodies wane after several months and in some cases become undetectable even with the most sensitive antibody assays [16]. Highly specific T-cell assays may help proving specificity of low positive or grey-zone antibody results. In a recent study with COVID-19 convalescents, a cellular immune response had been detectable in 78% of non-seroconverting and 80% of seroconverting patients by ELISPOT using different peptide pools and proteins. The authors found highest specificity but lowest sensitivity using the S1 protein [18]. The EUROIMMUN IGRA uses only an

S1 peptide pool for stimulation; however, using the adapted cut-off specific IFN-y release was detected in 100% and 83.5% of individuals after infection less and more than 6 months ago, respectively.

For the use in vaccination studies quantification of the T-cell response must be reliable. We were able to show significant differences between the first and the second vaccination among groups as well as individuals and between different vaccines. Similar results have been reported recently in a study using the same IGRA [35]. Reproducibility was good and the assay showed high tolerance against variations of standard procedures (data not shown). These properties make the assay highly suitable for routine diagnostic laboratories and opens up possibilities to analyze the immune response beyond using antibody detection assays in vaccinated patients especially under immunosuppressing or immune modulating medications. Importantly, we were able to show that B-cell depleted patients in most cases mount a strong T-cell response to COVID-19 vaccination and are thus probably protected against severe disease [24]. However, this was not seen in patients after organ transplantation confirming previous studies [36]. These patients can only be protected by vaccination of their close contacts and non-pharmaceutical intervention strategies.

Limitation for the use of such a biological assay is the functionality of the T-cell response. Even low-dose steroid treatment may interfere with IGRA testing, as has been shown for Quantiferon TB in immunocompetent children (34). We have seen in one of our patients that even short-term steroid treatment may be of relevance. The patient yielded a negative mitogen control and a negative response to SARS-CoV-2 antigen (46 and 15 mIU/mI) three weeks after vector/mRNA heterologous vaccination, but SARS-CoV-2 S1-IgG was detectable. She was on high dose steroids when blood was drawn, but not during vaccination. After stopping steroid treatment, we repeated the assay and detected 985 mIU/mI after antigen stimulation with high positive mitogen control (1880 mIU/mI). Further, the interpretation of grey-zone results is always difficult, so we developed a double cut-off

References

343

- 1. McMahan K, Yu J, Mercado NB, et al. Correlates of protection against SARS-CoV-2 in rhesus
- 345 macaques. Nature **2021**; 590:630-4.
- 2. Bertoletti A, Tan AT, Le Bert N. The T cell response to SARS-CoV-2: kinetic and quantitative aspects
- and the case for their protective role. Oxford Open Immunology **2021**:iqab006.
- 348 3. Hellerstein M. What are the roles of antibodies versus a durable, high quality T-cell response in
- protective immunity against SARS-CoV-2? Vaccine: X **2020**; 6:100076.
- 4. Sester M, Sotgiu G, Lange C, et al. Interferon-γ release assays for the diagnosis of active
- tuberculosis: a systematic review and meta-analysis. The European respiratory journal **2011**; 37:100-
- 352 11.
- 353 5. Paouri B, Soldatou A, Petrakou E, et al. Quantiferon-Cytomegalovirus assay: A potentially useful
- tool in the evaluation of CMV-specific CD8+ T-cell reconstitution in pediatric hematopoietic stem cell
- transplant patients. Pediatric transplantation **2018**; 22:e13220.
- 356 6. Terada K, Itoh Y, Fujii A, Kitagawa S, Ogita S, Ouchi K. Varicella-zoster virus-specific, cell-mediated
- immunity with interferon-gamma release assay after vaccination of college students with no or
- intermediate IgG antibody response. Journal of medical virology 2015; 87:350-6.
- 7. Murugesan K, Jagannathan P, Pham TD, et al. Interferon-gamma release assay for accurate
- detection of SARS-CoV-2 T cell response. Clin Infect Dis 2020.
- 361 8. Haas EJ, Angulo FJ, McLaughlin JM, et al. Impact and effectiveness of mRNA BNT162b2 vaccine
- against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a
- an ationwide vaccination campaign in Israel: an observational study using national surveillance data.
- 364 The Lancet **2021**; 397:1819-29.
- 365 9. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-
- 366 AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older
- adults in England: test negative case-control study. BMJ **2021**; 373:n1088.

- 368 10. Tyagi K, Ghosh A, Nair D, et al. Breakthrough COVID19 infections after vaccinations in healthcare
- and other workers in a chronic care medical facility in New Delhi, India. Diabetes Metab Syndr 2021;
- 370 15:1007-8.
- 371 11. CDC. https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html.
- 372 Available at: https://www.cdc.gov/vaccines/covid-19/health-departments/breakthrough-cases.html.
- 12. Tyagi K, Ghosh A, Nair D, et al. Breakthrough COVID19 infections after vaccinations in healthcare
- and other workers in a chronic care medical facility in New Delhi, India. Diabetes & Metabolic
- 375 Syndrome: Clinical Research & Reviews **2021**; 15:1007-8.
- 376 13. Teran RA, Walblay KA, Shane EL, et al. Postvaccination SARS-CoV-2 infections among skilled
- 377 nursing facility residents and staff members Chicago, Illinois, December 2020-March 2021. Am J
- 378 Transplant **2021**; 21:2290-7.
- 379 14. Hacisuleyman E, Hale C, Saito Y, et al. Vaccine Breakthrough Infections with SARS-CoV-2 Variants.
- 380 New England Journal of Medicine **2021**; 384:2212-8.
- 15. Melidou A, Pereyaslov D, Hungnes O, et al. Virological surveillance of influenza viruses in the
- 382 WHO European Region in 2019/20 impact of the COVID-19 pandemic. Euro Surveill 2020; 25.
- 383 16. Aubry A, Demey B, François C, et al. Longitudinal Analysis and Comparison of Six Serological
- Assays up to Eight Months Post-COVID-19 Diagnosis. J Clin Med **2021**; 10.
- 385 17. Song CC, Christensen J, Kumar D, Vissichelli N, Morales M, Gupta G. Early Experience with SARs-
- 386 CoV-2 mRNA Vaccine Breakthrough Among Kidney Transplant Recipients. Transpl Infect Dis
- 387 **2021**:e13654.
- 388 18. Schwarzkopf S, Krawczyk A, Knop D, et al. Cellular Immunity in COVID-19 Convalescents with PCR-
- 389 Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG. Emerg Infect Dis 2021; 27.
- 390 19. Reynolds CJ, Swadling L, Gibbons JM, et al. Discordant neutralizing antibody and T cell responses
- in asymptomatic and mild SARS-CoV-2 infection. Sci Immunol **2020**; 5.
- 392 20. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell **2021**; 184:861-80.

- 393 21. Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific Adaptive Immunity to SARS-
- 394 CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell 2020; 183:996-
- 395 1012.e19.
- 396 22. Soresina A, Moratto D, Chiarini M, et al. Two X-linked agammaglobulinemia patients develop
- 397 pneumonia as COVID-19 manifestation but recover. Pediatric Allergy and Immunology **2020**; 31:565-
- 398 9.
- 399 23. Montero-Escribano P, Matías-Guiu J, Gómez-Iglesias P, Porta-Etessam J, Pytel V, Matias-Guiu JA.
- 400 Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from
- 401 Madrid, Spain. Multiple Sclerosis and Related Disorders **2020**; 42:102185.
- 402 24. Bange EM, Han NA, Wileyto P, et al. CD8+ T cells contribute to survival in patients with COVID-19
- and hematologic cancer. Nature Medicine **2021**.
- 404 25. Redd AD, Nardin A, Kared H, et al. CD8+ T cell responses in COVID-19 convalescent individuals
- 405 target conserved epitopes from multiple prominent SARS-CoV-2 circulating variants. Open Forum
- 406 Infectious Diseases 2021:ofab143.
- 407 26. Tarke A, Sidney J, Methot N, et al. Negligible impact of SARS-CoV-2 variants on CD4 (+) and CD8
- 408 (+) T cell reactivity in COVID-19 exposed donors and vaccinees. bioRxiv 2021.
- 409 27. Woldemeskel BA, Garliss CC, Blankson JN. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell
- responses that recognize SARS-CoV-2 variants and HCoV-NL63. J Clin Invest **2021**; 131.
- 411 28. Geers D, Shamier MC, Bogers S, et al. SARS-CoV-2 variants of concern partially escape humoral
- but not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci Immunol 2021; 6.
- 413 29. Wang Z, Schmidt F, Weisblum Y, et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and
- 414 circulating variants. Nature **2021**; 592:616-22.
- 30. Hagen J, Zimmerman R, Goetz C, et al. Comparative Multi-Donor Study of IFNγ Secretion and
- Expression by Human PBMCs Using ELISPOT Side-by-Side with ELISA and Flow Cytometry Assays. Cells
- **2015**; 4:84-95.
- 418 31. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and
- 419 TH1 T cell responses. Nature **2020**; 586:594-9.

32. Rutjes AW, Reitsma JB, Coomarasamy A, Khan KS, Bossuyt PM. Evaluation of diagnostic tests when there is no gold standard. A review of methods. Health Technol Assess 2007; 11:iii, ix-51. 33. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 2020; 181:1489-501.e15. 34. Braun J, Loyal L, Frentsch M, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature **2020**; 587:270-4. 35. Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study. medRxiv 2021:2021.05.19.21257334. 36. Sattler A, Schrezenmeier E, Weber U, et al. Impaired Humoral and Cellular Immunity after SARS-CoV2 BNT162b2 (Tozinameran) Prime-Boost Vaccination in Kidney Transplant Recipients. medRxiv :2021.04.06.21254963.

Figure legend

Figure 1: IFN-y release after stimulation with SARS-CoV-2 spike antigen in different groups.

Differences are highly significant with p<0.001 unless indicated. BNT162b2-1 and -2 denotes health care workers (HCW) after the first and second dose of BNT162b2 (n=38), AZD1222 denotes HCW after first dose of AZD1222 (n=30) and AZD1222+mRNA1273 after the second dose with mRNA-1273 (heterologous vaccination scheme, n=27). ns= not significant




Table 1. Baseline characteristics of the 230 health care workers.

	COVID-19	COVID-19	Vaccine group	Vaccine	Vaccine	No COVID-
	>6	<6	BNT162b2,	group	group	19 group,
	months	months	n=38	AZD1222,	AZD1222/	n=55
	ago, n=91	ago, n=16		n=30	mRNA-1273,	
					n=27	
Age in	43.9 (22 -	38.1 (22 -	42.6 (19 - 63)	44.2 (23 - 64)	44.9 (23 -	42.58 (20 -
years,	64)	60)			64)	70)
mean						
(range)						
Sex						
Female %	64.8	50	76.3	88.9	88.9	67.3
Male %	35.2	50	23.7	11.1	11.1	32.7

Table 2: SARS-CoV-2 antibody results of three IFN-y positive individuals of the "no COVID-19" group.

Sample ID	S1-IgG ELISA,	N-IgG ELISA,	S1/RBD total AB,	N total AB, Roche
	EUROIMMUN	Mikrogen	Siemens	
94	0.435 (negative)	26.8 (equivalent)	4.45 (positive)	22.2 (positive)
95	1.2 (positive)	5.73 (negative)	>10.00 (positive)	2.4 (positive)
100	1.52 (positive)	14.7 (negative)	>10.00 (positive)	27.7 (positive)

Table 3: Diagnostic test accuracy of the EUROIMMUN interferon- γ release assay using different cutoffs at an estimated COVID-19 prevalence of 10%.

	Cut-off >100 mIU/ml	Cut-off ≥135 mIU/ml	Adapted cut-off*
Sensitivity % (95% CI)	89.6 (82.2 - 94.7)	88.7 (81.1 - 94.0)	86.8 (78.8 - 92.6)
Specificity	96.2 (86.8 - 99.5)	98.1 (89.7 - 99.9)	100 (93.2 - 100)
Negative predictive value	98.8 (97.9 - 99.3)	98.7 (97.9 - 99.3)	98.6 (97.7 - 99.1)
Positive predictive value	72.2 (39.9 - 90.9)	83.7 (42.4 - 97.3)	100
Accuracy	95.5 (90.9 - 98.2)	97.1 (93.2 - 99.1)	98.7 (95.4 - 99.8)

^{*}Adapted cut-off: Cut-off ≥135 mIU/ml if BLANK < 100 mIU/ml and ≥200mIU/ml if BLANK ≥100

mIU/ml mIU/ml

Table 4: Interferon- γ results in mIU/ml in the different study groups.

Study group	n	mean	SD*	median	min	max
No COVID-19	52	20.37	37.8	2.0	0	193
Past infection >6mo	90	885.1	1584.1	355.5	17	12149
Past infection <6mo	16	1205.9	1224.3	837.5	151	5383
BNT162b2 1. dose	38	2444.6	5522.4	1007.5	7	34300
BNT162b2 2. dose	38	14268.6	18437.0	5197.5	245	67049
AZD1222 1. dose	30	9847.1	17207.0	1421.0	64	67748
AZD1222/mRNA1273	27	6492.0	16969.2	4440.0	245	67049

^{*}SD Satn

Table 5. Combined immune response (detection of SARS-CoV-2 S1-IgG and/or IFN-y response) to vaccination in immunocompromised patients and healthy adults.

Underlying	S1-IgG negative	IGRA positive,	S1-IgG positive,	IGRA and S1-IgG	IGRA
disease	AND IGRA	S1-IgG negative	IGRA negative or	positive	invalid
	negative or		invalid		
	invalid	N (%)	N (%)	N (%)	N (%)
	N (%)				
Lung transplant	29 (87,9)	1 (3.0)	2 (6.0)	1 (3.0)	8 (24.2)
(n=33)					
Kidney transplant	14 (58.3)	3 (12.5)	5 (20.8)	2 (8.3)	9 (37.5)
(n=24)					
Haemato-	12 (50)	6 (25.0)	2 (8.3)	4 (16.6)	3 (12.5)
oncological					
(n=24)					
Stem cell	3 (15.8)	3 (15.8)	6 (31.6)	7 (36.8)	3 (15.8)
transplant (n=19)					
Autoimmune	7 (20.0)	14 (40.0)	4 (11.4)	10 (28.6)	2 (5.7)
disorder (n=35)					
Variable	6 (42.9)	1 (7.1)	1 (7.1)	6 (42.8)	0
immunodeficienc					
y (n=14)					
HCW BNT162b2	0	0	0	38 (100)	0
(n=38)					
HCW	0	0	0	27 (100)	0
AZD1222/mRNA1					
273 (n=27)					